NAMPT
Nicotinamide phosphoribosyl transferase; PBEF; Visfatin; pre-B cell-enhancing factor; Pre-B cell colony enhancing factor
Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme which catalyzes the conversion of nicotinamide (NAM) and phosphoribosyl-pyrophosphates to nicotinamide mononucleotide (NMN) in the mammalian nicotinamide adenine dinucleotide (NAD+) synthetic salvage pathway. NAMPT exists in two forms, intracellular NAMPT (iNAMPT) and extracellular NAMPT (eNAMPT).
iNAMPT levels are high in brown adipose tissue (BAT), liver and kidney, intermediate in white adipose tissue (WAT), lung, spleen, testes and skeletal muscle, and undetectable in brain and pancreas. eNAMPT, thought to be produced through post-translational modification of iNAMPT, is released into plasma predominantly from adipose tissue, where it catalyses the synthesis of NMN. Although intracellular NAMPT is a key enzyme in controlling NAD metabolism, eNAMPT has been reported to function as a cytokine, with many roles in physiology and pathology. Circulating eNAMPT has been associated with several metabolic and inflammatory disorders, including cancer.
All Product Categories
-
NAMPT Verwandte Produkte (91)
Verwandte Produkte (91)
-
Antibodies (2)
-
Daporinad
0 ImagesSynonyms: FK866; APO866Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression.
-
Padnarsertib
0 ImagesSynonyms: KPT-9274
-
CHS-828
0 ImagesSynonyms: GMX1778CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity.
-
SBI-797812
0 ImagesSBI-797812 is an orally active nicotinamide phosphoribosyltransferase (NAMPT) activator. SBI-797812 shifts NAMPT to NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. SBI-797812 increases intracellular nicotinamide mononucleotide (NMN) and elevates liver NAD+ in mice.
-
PROTAC NAMPT Degrader-30
0 ImagesPROTAC NAMPT Degrader-30 is a PROTAC degrader targeting nicotinamide phosphoribosyltransferase (NAMPT), with a DC50 of 8.4 nM in A2780 cells. PROTAC NAMPT Degrader-30 binds to the VHL E3 ligase and forms a ternary complex with NAMPT, which induces ubiquitination and subsequent proteasomal degradation of NAMPT, thereby inhibiting the enzymatic activity of NAMPT. PROTAC NAMPT Degrader-30 reduces intracellular NAD+ levels and suppresses tumor cell proliferation. PROTAC NAMPT Degrader-30 exhibits a fluorescence turn-on response to the NAMPT protein, enabling real-time visualization of the NAMPT degradation process in living cells. PROTAC NAMPT Degrader-30 is applicable for research on ovarian cancer.
-
LYP-8
0 ImagesLYP-8 is an intracellular nicotinamide phosphoribosyltransferase (iNAMPT) PROTAC degrader with an IC50 of 0.76 μM. LYP-8 recruits VHL E3 ligase to induce iNAMPT polyubiquitination and proteasome-dependent degradation, and inhibits iNAMPT enzymatic activity. LYP-8 reduces eNAMPT levels by degrading iNAMPT to decrease eNAMPT secretion. LYP-8 reduces intracellular NAD+ levels in cancer cells and proinflammatory cytokine levels (IL-6, TNF-α) in tumor tissue and serum. LYP-8 can be used for the research of colon cancer.
-
NAMPT/PD-1/PD-L1-IN-1
0 ImagesArt. -Nr.: HY-184918CAS. Nr.: 3097045-01-4NAMPT/PD-1/PD-L1-IN-1 is a potent the PD-1/PD-L1 interaction and NAMPT dual inhibitor with IC50s of 7.5 nM and 18.8 nM, respectively. NAMPT/PD-1/PD-L1-IN-1 enhances T cell-mediated tumor cell killing, promotes T cell proliferation and CD8+ T cell proportion and depletes intracellular NAD+ biosynthesis. NAMPT/PD-1/PD-L1-IN-1 suppresses tumor progression in a mouse LLC xenograft model by disrupting tumor metabolism and activating the tumor immune microenvironment. NAMPT/PD-1/PD-L1-IN-1 can be used in research on tumor immunotherapy for non-small cell lung cancer.
-
ALT-100 (Human IgG4)
0 ImagesArt. -Nr.: HY-P990319Reinheit: ≥99.0%ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
-
Nampt activator-3
0 ImagesNAMPT activator-3, a NAT derivative, is a NAMPT activator with an EC50 of 2.6 μM and a KD of 132 nM. NAMPT activator-3 effectively protects cultured cells from FK866 (HY-50876)-mediated toxicity. NAMPT activator-3 exhibits strong neuroprotective efficacy in a chemotherapy-induced peripheral neuropathy (CIPN) mouse model without any overt toxicity.
-
STF-118804
0 ImagesSTF-118804 is a highly specific NAMPT inhibitor. STF-118804 activates AMPK and inhibits mTOR pathways. STF-118804 has antitumor activity against pancreatic cancer.
-
Nampt-IN-1
0 ImagesSynonyms: LSN3154567
-
NAMPT inhibitor-linker 2
0 ImagesArt. -Nr.: HY-112616CAS. Nr.: 2241014-82-2NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC50s of <7 pM and 40 pM, respectively.
